Investors should buy these FTSE stalwarts in March!

Dr James Fox details some of his top FTSE stocks to buy in March after the latest earnings season caused some market volatility.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE still offers great value, despite this year’s rally. In fact, if I were an American investor, I’d be looking almost exclusively at the index in an attempt to find value and develop my portfolio for the long run. UK stocks have some of the most attractive valuations around the world right now.

Today, I’m looking at two UK stocks that investors should buy in March. So let’s take a closer look at them.

Smith & Nephew

Smith & Nephew (LSE:SN) reported full-year revenue of $5.22bn on Tuesday. This was up 4.7% on an underlying year-on-year basis, with growth linked to positive performances across all franchises and geographies.

Trading profit for the year came in at $901m, down from $936m. The company reported a trading profit margin of 17.3%, down from 18% in 2021. The fall was attributed to inflationary pressure.

Reported growth was only 0.1%, due to the negative impact of foreign exchange headwinds

Looking forward, Smith & Nephew reported progress on its 12-point plan, which aims to drive growth in advanced wound management, sports medicine and orthopaedics.

This, in turn, contributes to a forecast 5-6% revenue growth for 2023, and a trading profit margin of at least 17.5%. With regards to longer-term objectives, Smith & Nephew said it was aiming for at least 5% underlying revenue growth and a trading profit margin expansion to at least 20% by 2025.

I’m aware of the ongoing and challenging impact of inflation, as well as the underfunded nature of healthcare.

However, I think are some massive tailwinds here. Firstly, there’s a huge backlog for elective procedures, and we have an ageing population challenge in most Western countries. This should translate into more business for the hip-replacement specialist.

The stock trades with a forward price-to-earnings (P/E) of 15 — a little above the index average but a very attractive ratio for healthcare.

Barclays

Barclays (LSE:BARC) disappointed investors last week, after the FTSE stalwart posted a pre-tax profit of £7bn for 2022, missing estimates of £7.2bn. In fact, after the announcement, the share price fell over 10%.

I thought this was something of an overreaction — although I appreciated that the £500m share buy-back left the City underwhelmed. So I bought more of the stock, with P/E at just 5.5.

There were several further positives within the report. Barclays is targeting a 2023 net interest margin of more than 3.2%, up from 2.86% at the end of 2022.

We can also assume that the interest rate tailwind will continue for several years. Inflation is proving stickier than anticipated, so interest rates could stay higher for longer. In the US, we can also see that economic activity has been less vulnerable to rising rates than originally thought — this could prove the case in the UK too.

Furthermore, Barclays uses a hedging strategy, providing a smoothing impact for rate hikes and extending the net interest gains over a longer period of time.

Finally, I appreciate there are challenges, especially around bad debt. Last year, the bank’s performance was dragged down by sizeable £1.22bn in impairment charges. However, I’m confident Barclays can continue to perform in this environment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in Barclays Plc and Smith & Nephew Plc. The Motley Fool UK has recommended Barclays Plc and Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »